Coronavirus-like particles (CoVLP), which are produced in plants, combined with an adjuvant (Adjuvant System 03 [AS03]) forms a candidate vaccine that is effective for preventing COVID-19.
Routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications.
Masks are no longer necessary in outdoor waiting areas or open-air seating for fully vaccinated people who use public transportation.
The pivotal phase 3 PREVENT-19 trial evaluated the efficacy, safety and immunogenicity of NVX-CoV2373 in 29,960 participants 18 years of age and older in the US and Mexico.
The extension was based on data from ongoing stability assessment studies.
A proposal to ease patents and related protections on COVID-19 vaccines in order to help developing nations fight the pandemic will be considered at a two-day meeting of a World Trade Organization (WTO) panel.
Catch-up vaccinations for routine childhood and adolescent vaccinations are lagging behind after a decline during March to May 2020.
Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its COVID-19 vaccine, announced Monday that its two-shot regimen was more than 90% effective overall in a trial that unfolded even as more contagious variants emerged.
The highly contagious coronavirus variant that brought India to its knees this spring now accounts for 6% of new cases in the United States, the Biden administration said Tuesday.
US federal and state health officials are trying to administer as many doses as possible of the Johnson & Johnson COVID-19 vaccine as millions of unused shots are set to expire this month.
